Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll Novartis won't be pulling the trigger on a $ 600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder ...

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

Eric Palmer The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's ...

ProPublica: Safety questions over GSK’s Advair linger after years on the asthma throne

Carly Helfand U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $ 8 billion ...

Third Rock eyes a Cambridge, MA, beachhead as biotech gets priced out

Damian Garde As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to ...

Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys

Emily Wasserman Spring is in the air, and Actavis is starting to see the fruits of last year's M&A. The company reported first-quarter earnings that beat expectations–and ...

MorphoSys bags a peptide biotech for $22M

Damian Garde MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($ 22 million) for the shares it didn't already own and picking up a handful ...

Caforio takes CEO role as BMS faces tough year with promising new drugs

Eric Palmer Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today ...

Symbiomix pops out of stealth mode with $41M and a looming PhIII

John Carroll In the little more than two years since its launch, Symbiomix Therapeutics has successfully navigated a midstage study for a sole-asset antibiotic, positioning it for a ...

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

Eric Palmer It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of ...

One ‘cultural difference’ between Teva and Mylan? Coury’s $22.5M pay wouldn’t fly at Teva

Carly Helfand Since before Teva even made its now-rejected $ 40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a ...

Lilly’s new insulin is likely DOA after latest delay, analyst says

Damian Garde Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting ...

FDA grants Celgene’s Revlimid new use as it moves toward $10B in sales

Eric Palmer Celgene's powerhouse cancer drug Revlimid generated nearly $ 5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will ...
Page 5 of 50« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS